 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- IOH-001 / Immuneoncia Therap
IOH-001, a novel CD47/PD-L1 bispecific antibody, enhances anti-tumor activity in solid tumors (Section 38) - Mar 9, 2022 - Abstract #AACR2022AACR_2784;
Bispecific antibody IOH-001 is more likely to work better in targeting tumor cells than the combination of anti-CD47 and anti-PD-L1. Preclinical efficacy results of IOH-001 provide a strong rationale for assessing therapeutic potential in clinical studies.